Last reviewed · How we verify
Eltrombopag (EPAG)
Eltrombopag is a thrombopoietin (TPO) receptor agonist that stimulates platelet production by binding to and activating the TPO receptor on bone marrow megakaryocytes.
Eltrombopag is a thrombopoietin (TPO) receptor agonist that stimulates platelet production by binding to and activating the TPO receptor on bone marrow megakaryocytes. Used for Chronic immune thrombocytopenia (ITP), Thrombocytopenia associated with chronic hepatitis C, Severe aplastic anemia.
At a glance
| Generic name | Eltrombopag (EPAG) |
|---|---|
| Also known as | Promacta |
| Sponsor | Centro de Atencion e Investigacion Medica |
| Drug class | Thrombopoietin receptor agonist |
| Target | TPO receptor (c-Mpl) |
| Modality | Small molecule |
| Therapeutic area | Hematology |
| Phase | FDA-approved |
Mechanism of action
Eltrombopag is a small-molecule, orally bioavailable TPO receptor agonist that mimics the action of endogenous thrombopoietin. By activating the TPO receptor (also known as c-Mpl) on megakaryocyte progenitor cells in the bone marrow, it promotes megakaryocyte proliferation and differentiation, leading to increased platelet production. This mechanism makes it useful in conditions characterized by thrombocytopenia (low platelet counts).
Approved indications
- Chronic immune thrombocytopenia (ITP)
- Thrombocytopenia associated with chronic hepatitis C
- Severe aplastic anemia
Common side effects
- Headache
- Diarrhea
- Nausea
- Fatigue
- Thromboembolic events
Key clinical trials
- rhTPO Dose Escalation vs Eltrombopag Switch in ITP (NA)
- Early Initiation of Oral Therapy With Cyclosporine and Eltrombopag for Treatment Naive Severe Aplastic Anemia (SAA) (PHASE2)
- Sequential rhTPO and Eltrombopag Following Glucocorticoids for Severe Adult ITP (PHASE4)
- Eltrombopag as a Novel Therapeutic Approach for Low-risk MDS and CMML With TET2 Mutations (PHASE2)
- Bioequivalence Study of Revolade® Eltrombopag 50 mg (PHASE4)
- Study on the Short-term Efficacy and Safety of Recombinant Human Thrombopoietin Combined With Immunosuppressant Sequential Eltrombopag Ethanolamine Dry Suspension in the Treatment of SAA/TD-NSAA (PHASE3)
- Treatment of Refractory Diamond-Blackfan Anemia With Eltrombopag (PHASE1, PHASE2)
- Eltrombopag With Standard Immunosuppression for Severe Aplastic Anemia (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Eltrombopag (EPAG) CI brief — competitive landscape report
- Eltrombopag (EPAG) updates RSS · CI watch RSS
- Centro de Atencion e Investigacion Medica portfolio CI